SCHEMBL4151619

SCHEMBL4151619

CNC(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.66
CYP3A4 P08684 1/20 0.66
CYP2C9 P11712 1/20 0.66
TSHR P16473 1/20 0.66
CYP2C19 P33261 1/20 0.66
CA12 O43570 1/20 0.63
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63
CA4 P22748 1/20 0.63
CA6 P23280 1/20 0.63
CA7 P43166 1/20 0.63
TPMT P51580 1/20 0.63
CA9 Q16790 1/20 0.63
CA14 Q9ULX7 1/20 0.63
MAPT P10636 3/20 0.61
ALOX15 P16050 1/20 0.61
MAPK1 P28482 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28826077 0.90 MAPT (0.58) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL12682342 0.86 MAPT (0.71) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL12062652 0.85 TAS1R3 (0.60) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL6993698 0.85 CA12 (0.65) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL3587188 0.85 CYP1A2 (0.61) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL19431210 0.85 MAPT (0.65) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL9103250 0.85 TAS1R3 (0.56) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL19519009 0.85 PDE4D (0.60) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL5758000 0.85 MEN1 (0.68) CYP1A2MAPTALOX15MAPK1KMT2A
SCHEMBL1436474 0.85 SMPD1 (0.66) CYP1A2CYP3A4CYP2C9TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119591657-B Cyclovirobuxine D derivative, and preparation method and application thereof 中国药科大学 2026-05-22 CN disclosed
CN-119591657-A Cyclovirobuxine D derivative, and preparation method and application thereof 中国药科大学 2025-03-11 CN disclosed
WO-2023220440-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-11-16 WO disclosed
WO-2023091644-A2 HSD17B13-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-05-25 WO disclosed
WO-2023049218-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-03-30 WO disclosed
WO-2022099159-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2022-05-12 WO disclosed
WO-2021234459-A9 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2022-02-03 WO disclosed
WO-2021237223-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2021-11-25 WO disclosed
WO-2021234459-A2 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2021-11-25 WO disclosed
WO-2019199800-A1 SMALL MOLECULE MODULATORS OF PAR2 AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2019-10-17 WO disclosed
US-20090075909-A1 Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds RANBAXY LABORATORIES LIMITED INC. (IN) 2009-03-19 US disclosed
US-20090075909-A1 Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds RANBAXY LABORATORIES LIMITED INC. (IN) 2009-03-19 US disclosed
US-20080153821-A1 Nitrogen-containing 5-membered ring compound TANABE SEIYAKU CO., LTD. 2008-06-26 US disclosed
US-7332487-B2 Nitrogen-containing 5-membered ring compound TANABE SEIYAKU CO., LTD. (JP) 2008-02-19 US disclosed
US-6245779-B1 ANALGESICS; ANTIINFLAMMATORY AGENTS OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2001-06-12 US disclosed
EP-0997463-A1 NAPHTHYRIDINE DERIVATIVES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2000-05-03 EP disclosed
EP-0030009-B1 NEW DERIVATIVES OF THE 9-CIS-6,6'-DIAPO-PSI,PSI-CAROTENEDIOIC ACID, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Simes S.p.A. (IT) 1983-05-11 EP disclosed
US-4342875-A STABILIZERS FOR OLEFIN POLYMERS CINCINNATI-MILACRON, INC. (US) 1982-08-03 US disclosed
EP-0030009-A1 New derivatives of the 9-cis-6,6'-diapo-psi,psi-carotenedioic acid, preparation thereof and pharmaceutical compositions containing same Simes S.p.A. (IT) 1981-06-10 EP disclosed
US-3959269-A TRANQUILIZERS, SEDATIVES SANDOZ, INC. (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075909-A1 Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds HLA-DRB1, IL5, TNF CYP1A2 2700/4885CYP3A4 3054/4885CYP2C9 3613/4885
US-20080153821-A1 Nitrogen-containing 5-membered ring compound ALK, SCO2, NPR1 CYP1A2 212/4885CYP3A4 722/4885CYP2C9 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.